Jennifer L. McNeer
No Rating Available
(Learn About Our Rating System)

Jennifer L. McNeer, MD, MSCI

Languages spoken: English

Clinical Locations

Primary Location

Primary Children's Hospital

Pediatric Hematology/Oncology
100 N Mario Capecchi Drive
Salt Lake City , UT 84113
801-662-4830
Get Directions

  • Dr. McNeer is a Professor of Clinical Pediatrics at the University of Utah School of Medicine in the Division of Pediatric Hematology/Oncology and is the Medical Director for Pediatric Hematology/Oncology at Primary Children’s Hospital. She is a member of the Leukemia and Lymphoma team at the University of Utah and Primary Children’s Hospital.

    After receiving her medical degree from New York University School of Medicine, Dr. McNeer completed her residency at Children’s Memorial Hospital (now Lurie Children’s Hospital), which is affiliated with Northwestern University Feinberg School of Medicine. She then completed her fellowship in Pediatric Hematology/Oncology/Stem Cell Transplant at Children’s Memorial Hospital, and during her fellowship earned a master’s degree in clinical investigation at Northwestern University Feinberg School of Medicine.

    Dr. McNeer is board-certified in Pediatrics and Pediatric Hematology and Oncology. She has authored over 25 peer-reviewed journal articles and 4 book chapters. Dr. McNeer has been an invited speaker at many national and international conferences and symposiums. She is a member of the American Society of Clinical Oncology, American Society of Hematology, as well as the American Society of Pediatric Hematology/Oncology and the Children’s Oncology Group.

    Dr. McNeer’s clinical expertise is in the treatment of children, adolescents, and young adults with hematologic malignancies such as leukemia and lymphoma, in particular those with high-risk and relapsed/refractory acute lymphoblastic leukemia. She has a leadership role within the Children’s Oncology Group Acute Lymphoblastic Leukemia committee, and partners with colleagues in adult oncology to collaborate in developing treatment protocols and clinical trials for young adults with leukemia. Her research focus is on the design and implementation of clinical trials for patients with hematologic malignancies.

    Dr. McNeer is invested in improving overall treatment outcomes for children, adolescents, and young adults, while tailoring therapy and supportive care to individual patients in order to minimize toxicity and optimize quality of life.

    Specialties

    Board Certification

    American Board of Pediatrics (Pediatrics)
    American Board of Pediatrics (Sub: Pediatric Hematology-Oncology)

  • Dr. McNeer is a Professor of Clinical Pediatrics at the University of Utah School of Medicine in the Division of Pediatric Hematology/Oncology and is the Medical Director for Pediatric Hematology/Oncology at Primary Children’s Hospital. She is a member of the Leukemia and Lymphoma team at the University of Utah and Primary Children’s Hospital.

    After receiving her medical degree from New York University School of Medicine, Dr. McNeer completed her residency at Children’s Memorial Hospital (now Lurie Children’s Hospital), which is affiliated with Northwestern University Feinberg School of Medicine. She then completed her fellowship in Pediatric Hematology/Oncology/Stem Cell Transplant at Children’s Memorial Hospital, and during her fellowship earned a master’s degree in clinical investigation at Northwestern University Feinberg School of Medicine.

    Dr. McNeer is board-certified in Pediatrics and Pediatric Hematology and Oncology. She has authored over 25 peer-reviewed journal articles and 4 book chapters. Dr. McNeer has been an invited speaker at many national and international conferences and symposiums. She is a member of the American Society of Clinical Oncology, American Society of Hematology, as well as the American Society of Pediatric Hematology/Oncology and the Children’s Oncology Group.

    Dr. McNeer’s clinical expertise is in the treatment of children, adolescents, and young adults with hematologic malignancies such as leukemia and lymphoma, in particular those with high-risk and relapsed/refractory acute lymphoblastic leukemia. She has a leadership role within the Children’s Oncology Group Acute Lymphoblastic Leukemia committee, and partners with colleagues in adult oncology to collaborate in developing treatment protocols and clinical trials for young adults with leukemia. Her research focus is on the design and implementation of clinical trials for patients with hematologic malignancies.

    Dr. McNeer is invested in improving overall treatment outcomes for children, adolescents, and young adults, while tailoring therapy and supportive care to individual patients in order to minimize toxicity and optimize quality of life.

    Board Certification and Academic Information

    Academic Departments Pediatrics -Professor (Clinical)
    Academic Divisions Hematology/Oncology
    Board Certification
    American Board of Pediatrics (Pediatrics)
    American Board of Pediatrics (Sub: Pediatric Hematology-Oncology)

    Education history

    Undergraduate Biology - University of Virginia B.A. (Hons)
    Professional Medical Medicine - New York University College of Medicine M.D.
    Residency Pediatrics - Northwestern University Feinberg School of Medicine Resident
    Fellowship Pediatric Hematology/Oncology/Stem Cell Transplant - Northwestern University Feinberg School of Medicine Fellow
    Graduate Training Clinical Investigation - Northwestern University Feinberg School of Medicine M.S.C.I

    Selected Publications

    Journal Article

    1. McNeer JL, Kletzel M, Rademaker A, Alford K, O'Day K, Schaefer C, Duerst R, Jacobsohn D (2010). Early elevation of C-reactive protein correlates with severe infection and nonrelapse mortality in children undergoing allogeneic stem cell transplantation. Biology of blood and marrow transplantation, 16(3), 350-7. (Read full publication)
    2. McNeer JL, Goussetis DJ, Sassano A, Dolniak B, Kroczynska B, Glaser H, Altman JK, Platanias L (2010). Arsenic trioxide-dependent activation of thousand-and-one amino acid kinase 2 and transforming growth factor-beta-activated kinase 1. Molecular pharmacology, 77(5), 828-35. (Read full publication)
    3. Goussetis DJ, Altman JK, Glaser H, McNeer JL, Tallman MS, Platanias L (2010). Autophagy is a critical mechanism for the induction of the antileukemic effects of arsenic trioxide. The Journal of biological chemistry, 285(39), 29989-97. (Read full publication)
    4. Alperstein W, Boren M, McNeer J (2015). Pediatric Acute Lymphoblastic Leukemia: From Diagnosis to Prognosis. Pediatric annals, 44(7), e168-74. (Read full publication)
    5. Muffly LS, Hlubocky FJ, Khan N, Wroblewski K, Breitenbach K, Gomez J, McNeer JL, Stock W, Daugherty C (2016). Psychological morbidities in adolescent and young adult blood cancer patients during curative-intent therapy and early survivorship. Cancer, 122(6), 954-61. (Read full publication)
    6. Petty LA, Sokol EA, Bartlett AH, McNeer JL, Alexander KA, Pisano (2016). Repeated Blood Cultures in Pediatric Febrile Neutropenia: Would Following the Guidelines Alter the Outcome?. Pediatric blood & cancer, 63(7), 1244-9. (Read full publication)
    7. Muffly L, Lichtensztajn D, Shiraz P, Abrahão R, McNeer J, Stock W, Keegan T, Gomez S (2017). Adoption of pediatric-inspired acute lymphoblastic leukemia regimens by adult oncologists treating adolescents and young adults: A population-based study. Cancer, 123(1), 122-130. (Read full publication)
    8. Yap KL, Furtado LV, Kiyotani K, Curran E, Stock W, McNeer JL, Kadri S, Segal JP, Nakamura Y, Le Beau MM, Gurbuxani S, Raca (2017). Diagnostic evaluation of RNA sequencing for the detection of genetic abnormalities associated with Ph-like acute lymphoblastic leukemia (ALL). Leukemia & lymphoma, 58(4), 950-958. (Read full publication)
    9. Villanueva G, de Jong JL, McNeer J (2017). Intravenous Immunoglobulin in the Treatment of Hematologic Disorders in Pediatrics. Pediatric annals, 46(1), e13-e18. (Read full publication)
    10. Henderson TO, Parsons SK, Wroblewski KE, Chen L, Hong F, Smith SM, McNeer JL, Advani RH, Gascoyne RD, Constine LS, Horning S, Bartlett NL, Shah B, Connors JM, Leonard JI, Kahl BS, Kelly KM, Schwartz CL, Li H, Friedberg JW, Friedman DL, Gordon LI, Evens A (2018). Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis. Cancer, 124(1), 136-144. (Read full publication)
    11. Henderson JR 2nd, Kiernan E, McNeer JL, Rodday AM, Spencer K, Henderson TO, Parsons S (2018). Patient-Reported Health-Related Quality-of-Life Assessment at the Point-of-Care with Adolescents and Young Adults with Cancer. Journal of adolescent and young adult oncology, 7(1), 97-102. (Read full publication)
    12. Bhojwani D, Sposto R, Shah NN, Rodriguez V, Yuan C, Stetler-Stevenson M, O'Brien MM, McNeer JL, Quereshi A, Cabannes A, Schlegel P, Rossig C, Dalla-Pozza L, August K, Alexander S, Bourquin JP, Zwaan M, Raetz EA, Loh ML, Rheingold S (2019). Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. Leukemia, 33(4), 884-892. (Read full publication)
    13. McNeer JL, Devidas M, Dai Y, Carroll AJ, Heerema NA, Gastier-Foster JM, Kahwash SB, Borowitz MJ, Wood BL, Larsen E, Maloney KW, Mattano L, Winick NJ, Schultz KR, Hunger SP, Carroll WL, Loh ML, Raetz E (2019). Hematopoietic Stem-Cell Transplantation Does Not Improve the Poor Outcome of Children With Hypodiploid Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group. Journal of clinical oncology, 37(10), 780-789. (Read full publication)
    14. Rubnitz JE, Lacayo NJ, Inaba H, Heym K, Ribeiro RC, Taub J, McNeer J, Degar B, Schiff D, Yeoh AE, Coustan-Smith E, Wang L, Triplett B, Raimondi SC, Klco J, Choi J, Pounds S, Pui C (2019). Clofarabine Can Replace Anthracyclines and Etoposide in Remission Induction Therapy for Childhood Acute Myeloid Leukemia: The AML08 Multicenter, Randomized Phase III Trial. Journal of clinical oncology, 37(23), 2072-2081. (Read full publication)
    15. Suh E, Stratton KL, Leisenring WM, Nathan PC, Ford JS, Freyer DR, McNeer JL, Stock W, Stovall M, Krull KR, Sklar CA, Neglia JP, Armstrong GT, Oeffinger KC, Robison LL, Henderson T (2020). Late mortality and chronic health conditions in long-term survivors of early-adolescent and young adult cancers: a retrospective cohort analysis from the Childhood Cancer Survivor Study. The Lancet. Oncology, 21(3), 421-435. (Read full publication)
    16. Advani AS, Larsen E, Laumann K, Luger SM, Liedtke M, Devidas M, Chen Z, Yin J, Foster MC, Claxton D, Coffan K, Tallman MS, Appelbaum FR, Erba H, Stone RM, Hunger SP, McNeer JL, Loh ML, Raetz E, Winick N, Carroll W, Larson RA, Stock (2021). Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia. Blood advances, 5(2), 504-512. (Read full publication)
    17. Pikman Y, Tasian SK, Sulis ML, Stevenson K, Blonquist TM, Apsel Winger B, Cooper TM, Pauly M, Maloney KW, Burke MJ, Brown PA, Gossai N, McNeer JL, Shukla NN, Cole PD, Kahn JM, Chen J, Barth MJ, Magee JA, Gennarini L, Adhav AA, Clinton CM, Ocasio-Martinez N, Gotti G, Li Y, Lin S, Imamovic A, Tognon CE, Patel T, Faust HL, Contreras CF, Cremer A, Cortopassi WA, Garrido Ruiz D, Jacobson MP, Dharia NV, Su A, Robichaud AL, Saur Conway A, Tarlock K, Stieglitz E, Place AE, Puissant A, Hunger SP, Kim AS, Lindeman NI, Gore L, Janeway KA, Silverman LB, Tyner JW, Harris MH, Loh ML, Stegmaier (2021). Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP Consortium. Cancer discovery, 11(6), 1424-1439. (Read full publication)
    18. Schulte R, Hinson A, Huynh V, Breese EH, Pierro J, Rotz S, Mixon BA, McNeer JL, Burke MJ, Orgel (2021). Levocarnitine for pegaspargase-induced hepatotoxicity in older children and young adults with acute lymphoblastic leukemia. Cancer medicine, 10(21), 7551-7560. (Read full publication)
    19. Kaumeyer B, Fidai S, Sukhanova M, Yap KL, Segal J, Raca G, Stock W, McNeer J, Lager AM, Gurbuxani (2022). MUC4 expression by immunohistochemistry is a specific marker for BCR-ABL1+ and BCR-ABL1-like B-lymphoblastic leukemia. Leukemia & lymphoma, 63(6), 1436-1444. (Read full publication)
    20. Elgarten CW, Thompson JC, Angiolillo A, Chen Z, Conway S, Devidas M, Gupta S, Kairalla JA, McNeer JL, O'Brien MM, Rabin KR, Rau RE, Rheingold SR, Wang C, Wood C, Raetz EA, Loh ML, Alexander S, Miller T (2022). Improving infectious adverse event reporting for children and adolescents enrolled in clinical trials for acute lymphoblastic leukemia: A report from the Children's Oncology Group. Pediatric blood & cancer, 69(11), e29937. (Read full publication)
    21. McNeer J (2011). The complex interplay between folate metabolism and risk of acute lymphoblastic leukemia. Leukemia & lymphoma, 52(9), 1621-2. (Read full publication)
    22. McNeer J (2014). The identity crisis of Krüppel-like factor 4. Leukemia & lymphoma, 55(8), 1703-4. (Read full publication)
    23. Gupta S, Maude SL, O'Brien MM, Rau RE, McNeer J (2020). How the COG is Approaching the High-Risk Patient with ALL: Incorporation of Immunotherapy into Frontline Treatment. Clinical lymphoma, myeloma & leukemia, 20 Suppl 1, S8-S11. (Read full publication)
    24. Craig ML, Bankovich AJ, McElhenny JL, Taylor R (2000). Clearance of anti-double-stranded DNA antibodies: the natural immune complex clearance mechanism. Arthritis and rheumatism, 43(10), 2265-75. (Read full publication)
    25. Gupta S, Rau RE, Kairalla JA, Rabin KR, Wang C, Angiolillo AL, Alexander S, Carroll AJ, Conway S, Gore L, Kirsch I, Kubaney HR, Li AM, McNeer JL, Militano O, Miller TP, Moyer Y, O'Brien MM, Okada M, Reshmi SC, Shago M, Wagner E, Winick N, Wood BL, Haworth-Wright T, Zaman F, Zugmaier G, Zupanec S, Devidas M, Hunger SP, Teachey DT, Raetz EA, Loh M (2025). Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children. The New England journal of medicine, 392(9), 875-891. (Read full publication)
    26. Asif H, McNeer JL, Ghanayem NS, Cursio JF, Kane J (2024). First-Line Respiratory Support for Children With Hematologic Malignancy and Acute Respiratory Failure. Critical care explorations, 6(4), e1076. (Read full publication)
    27. Monick SE, Hanson C, Hoehn KS, Hlubocky FJ, Stock W, Duvall A, McNeer J, Henderson T, Daugherty C, Wang A (2025). Feasibility of Symptom Burden Assessments and Early Palliative Care Integration in an Adolescent and Young Adult Leukemia Clinic. Journal of adolescent and young adult oncology, (Read full publication)
    28. Greenzang KA, Montgomery KE, DuVall A, Roth ME, Krailo M, Nuño MM, Renfro L, DelRocco N, Doski J, Kelly K, Castellino SM, McNeer J, O'Brien MM, Reed D, Janeway K, Hinds PS, Zupanec S, Parsons S (2025). Incorporation of patient-reported outcomes in pediatric cancer clinical trials: design, implementation, and dissemination. Journal of the National Cancer Institute, 117(9), 1764-1773. (Read full publication)

    Review

    1. McNeer JL, Nachman J (2010). The optimal use of steroids in paediatric acute lymphoblastic leukaemia: no easy answers. British journal of haematology, 149(5), 638-52. (Read full publication)
    2. McGregor S, McNeer J, Gurbuxani (2012). Beyond the 2008 World Health Organization classification: the role of the hematopathology laboratory in the diagnosis and management of acute lymphoblastic leukemia. Seminars in diagnostic pathology, 29(1), 2-11. (Read full publication)
    3. McNeer JL, Raetz E (2012). Acute lymphoblastic leukemia in young adults: which treatment?. Current opinion in oncology, 24(5), 487-94. (Read full publication)
    4. McNeer JL, Bleyer (2018). Acute lymphoblastic leukemia and lymphoblastic lymphoma in adolescents and young adults. Pediatric blood & cancer, 65(6), e26989. (Read full publication)
    5. Schulte RR, Madiwale MV, Flower A, Hochberg J, Burke MJ, McNeer JL, DuVall A, Bleyer (2018). Levocarnitine for asparaginase-induced hepatic injury: a multi-institutional case series and review of the literature. Leukemia & lymphoma, 59(10), 2360-2368. (Read full publication)
    6. McNeer JL, Rau RE, Gupta S, Maude SL, O'Brien M (2020). Cutting to the Front of the Line: Immunotherapy for Childhood Acute Lymphoblastic Leukemia. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 40, 1-12. (Read full publication)
    7. McNeer JL, Schmiegelow (2022). Management of CNS Disease in Pediatric Acute Lymphoblastic Leukemia. Current hematologic malignancy reports, 17(1), 1-14. (Read full publication)
    8. Gupta S, McNeer J, O'Brien M, Rau R, Teachey (2025). The challenge of deintensifying chemotherapy for children and adolescents with B-ALL in the immunotherapy era. Hematology. American Society of Hematology. Education Program, 2025(1), 229-235. (Read full publication)

    Editorial

    1. McNeer J (2015). Pediatric Hematology, Oncology, and Stem Cell Transplantation. Pediatric annals, 44(7), 278-9. (Read full publication)

    Letter

    1. Morales La Madrid A, Ouyang K, Raca G, Jamali M, Hyjek E, McNeer JL, Anastasi (2013). A case of pediatric ¿/¿ T-cell malignancy with t(8;14)(q24;q11)/MYC-TCR successfully treated with pulse type chemotherapy followed by stem cell transplant. Leukemia & lymphoma, 54(2), 403-5. (Read full publication)
    2. Raca G, Gurbuxani S, Zhang Z, Li Z, Sukhanova M, McNeer J, Stock (2015). RCSD1-ABL2 fusion resulting from a complex chromosomal rearrangement in high-risk B-cell acute lymphoblastic leukemia. Leukemia & lymphoma, 56(4), 1145-7. (Read full publication)

    Other

    1. Bhojwani D, Sposto R, Shah NN, Rodriguez V, Yuan C, Stetler-Stevenson M, O'Brien MM, McNeer JL, Quereshi A, Cabannes A, Schlegel P, Rossig C, Dalla-Pozza L, August K, Alexander S, Bourquin JP, Zwaan M, Raetz EA, Loh ML, Rheingold S (2019). Correction: Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. Leukemia, 33(4), 1061-1062. (Read full publication)